

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. and Teva Canada Limited that the shortages for Taro-Budesonide 0.125 mg/ml Inhalation Suspension (DIN 02494264) and Teva- Budesonide 0.125 mg/ml Inhalation Suspension (DIN 02465949), respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **April 6, 2022**. The following grouping was removed from the Critical Supply Product List on **March 7, 2022**.

BUDESONIDE

0.125 MG / ML INHALATION SUSPENSION

00002494264	TARO-BUDESONIDE 0.125 MG / ML INH SUS	TAR	\$ 0.1143
00002465949	TEVA-BUDESONIDE 0.125 MG / ML INH SUS	TEV	\$ 0.1143
00002229099	PULMICORT NEBUAMP	AZC	\$ 0.2375

Alberta Blue Cross has been advised by Apotex Inc. and Jamp Pharma Corporation that the shortages for Apo-Darifenacin 7.5 mg Extended-Release Tablet (DIN 02452510) and Jamp Darifenacin 7.5 mg Extended-Release Tablet (DIN 02491869), respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **May 12, 2022**. The following grouping was removed from the Critical Supply Product List on **April 12, 2022**.

DARIFENACIN HYDROBROMIDE

7.5 MG EXTENDED-RELEASE TABLET

00002452510	APO-DARIFENACIN 0.125 MG/ML INH SUS	APX	\$ 0.8058
00002491869	JAMP DARIFENACIN 0.125 MG/ML INH SUS	JPC	\$ 0.8058
00002273217	ENABLEX	SLP	\$1.6400

continued next page

continued from previous page

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage for Nestle Materna Tablet (DIN 80082297) manufactured by Nestle Canada Inc., Prenatal 100% Complete Multivitamin Tablet (DIN 80075639) manufactured by Jamieson Laboratories Ltd. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Nestle Canada Inc. has advised Alberta Blue Cross that the shortage for Nestle Materna Tablet (DIN 80082297) has been resolved.

As a result, Prenatal 100% Complete Multivitamin Tablet (DIN 80075639) will no longer be considered a temporary benefit for the *ADBL* after **April 15, 2022**. The following grouping was removed from the Critical Supply Product List on **March 17, 2022**.

DARIFENACIN HYDROBROMIDE

7.5 MG EXTENDED-RELEASE TABLET

00002452510	APO-DARIFENACIN 0.125 MG/ML INH SUS	APX	\$ 0.8058
00002491869	JAMP DARIFENACIN 0.125 MG/ML INH SUS	JPC	\$ 0.8058
00002273217	ENABLEX	SLP	\$1.6400

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Trurapi 100 unit/ml Injection Cartridge (DIN 02506564) and Trurapi Solostar 100 unit/ml Pen Injection (DIN 02506572) manufactured by Sanofi – Aventis, Novorapid Flextouch 100 unit/ml Injection (DIN 02377209) will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. The following grouping was added to the Critical Supply Product List **April 28, 2022**.

As of **April 20, 2022**, all claims Novorapid Flextouch 100 unit/ml Injection (DIN 02377209) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

